PYC THERAPEUTICS LIMITED — AGM Information 2021

Nov 16, 2021

==> picture [595 x 179] intentionally omitted <==

----- Start of picture text ----- 17 November, 2021----- End of picture text -----

Annual General Meeting – Conference Link

PYC Therapeutics (ASX:PYC) ( PYC or the Company ) reminds shareholders that the Annual General Meeting of the Company ( AGM ) will be held on Thursday 18 November 2021 at 9.00am AWST.

The Company has taken precautions to facilitate an in person meeting in accordance with Covid 19 Restrictions. The AGM will be held at the Auditorium, The Harry Perkins Institute of Medical Research, QEII Medical Centre, 6 Verdun Street, Nedlands, Western Australia.

Shareholders are welcome to view the Annual General Meeting proceedings by clicking on the following zoom conference facility or entering the Meeting ID and Passcode:

https://us02web.zoom.us/j/87295141737?pwd=SXhBRGdWK005Z1hLeHZiZE9wd2t6dz09

Meeting ID: 872 9514 1737 Passcode: 838584

The audio and video link to the AGM will be available 15 minutes prior to the commencement of the meeting. A recording will also be made available after the Annual General Meeting at the Investors & Media” page of the PYC website at https://pyctx.com/investor-center/.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize Cell Penetrating Peptides (CPPs), a revolutionary delivery technology designed to overcome the major challenges of current gene-based therapies. PYC believes its CPP technology provides safer, more effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which it has unveiled three preclinical stage assets. PYC’s discovery and laboratory operations are located in Australia and the Company recently launched an expansion into the U.S. for its preclinical, clinical, regulatory and business development operations. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

1

+61 8 6151 0994 | pyctx.com | ACN 098 391 961

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACTS: INVESTORS MEDIA info@pyctx.com info@pyctx.com

2

+61 8 6151 0992 | pyctx.com | ACN 098 391 961